Overview


According to FutureWise analysis the market for Biomarkers in 2023 is US$ 59.1 billion, and is expected to reach US$ 148.64 billion by 2031 at a CAGR of 12.20%.

Biomarkers indicate regular or irregular processes in the body, potentially indicating an underlying disease or condition. Various molecules, such as hormones, RNA, DNA, or proteins, can be biomarkers since they all indicate health. Biomarkers might be produced by the cancer tissue or other cells in the body in response to cancer. They can be found in the blood, urine, stool, bodily fluids, or tumor tissue. Notably, biomarkers are not only limited to cancer. There are biomarkers for multiple sclerosis, heart disease, and many other diseases. The use of biomarkers in clinical practice and clinical research has become so familiar that the acceptance of primary endpoints in clinical trials is now nearly unquestioned. In the case of specific biomarkers well characterized and frequently shown to predict relevant clinical outcomes across various treatments and populations accurately, this use is entirely justified and appropriate. In many cases, however, the “validity” of biomarkers is assumed, where it should continue to be evaluated and re-evaluated.

FutureWise Market Research has published a report that provides an insightful analysis of Biomarkers market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the Biomarkers market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • F.Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc
  • Abbott Laboratories
  • QIAGEN N.V.
  • PerkinElmer, Inc
  • Merck KGaA
  • Bio-Rad Laboratories
  • Enzo Biochem, Inc
  • Charles River Laboratories International Inc
  • Eurofins Scientific

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in the Biomarkers Market:

  • In March 2023 - Abbott announced the FDA clearance for the first commercial availability of laboratory traumatic brain injury (TBI) blood test, thereby making it broadly accessible by hospitals in the U.S. hospitals. The company's Alinity® i laboratory instrument-operated test that measures biomarkers in blood was aimed at offering clinicians an unbiased way to assess and quickly evaluate individuals with mild TBIs or concussions.
  • In February 2023 - Roche announced the expansion of its partnership with Janssen to enhance personalized healthcare solutions by integrating companion diagnostics. This deal expands activities to cover a diverse portfolio of companion diagnostics comprising tissue and blood-based biomarkers, digital pathology, and sequencing.

By Product & Services

  • Consumables
  • Services
  • Software

By Type

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamics Biomarkers
  • Prognostic Biomarkers
  • Validation Biomarkers

By Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalised Medicine
  • Disease Risk Assessment
  • Other Applications

By Disease Indication

  • Cancer
  • Infectious Diseases
  • Immune Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The growth trajectory of the region is fueled by several factors, including a substantial disease burden, heightened consumer awareness regarding biomarkers, proactive governmental initiatives, rapid technological progress, and enhancements in healthcare infrastructure. Moreover, the region's growth is propelled by the significant presence of key industry players, alongside diverse organic and inorganic advancements initiated by them. An example of this growth-driving trend is evident through Akoya Biosciences, Inc., which unveiled the PhenoCode signature panels in November 2022. These panels are designed for high-throughput spatial biomarker discovery, underscoring the innovative efforts by industry leaders to push the boundaries of scientific exploration and application.

Additionally, globally in the Product & Services category; consumables segment accounted for largest share and by Type, safety biomarkers accounted for largest share. The dominant market share held by safety biomarkers can be attributed primarily to their integral role in the drug discovery process. Their extensive utilization in this sphere serves as a major driving force for their prominence. Furthermore, the escalating investment in research and development endeavours aimed at devising novel diagnostic procedures is anticipated to further boost the utilization of safety biomarkers throughout the projected period. This investment underscores the industry's commitment to advancing diagnostic capabilities and underscores the continued growth of safety biomarkers in the diagnostic landscape.

By disease indication; Cancer accounted for largest share in the global market in 2022. The growth observed in this particular segment can be attributed to the rising demand for diagnostic tools that offer both rapid and accurate results, alongside an increase in the global prevalence of cancer. Notably, the Global Cancer Observatory reported approximately 19.3 million new cancer cases in 2020, accompanied by nearly 10 million cancer-related deaths within the same year. The global scenario underscores cancer as the second leading cause of mortality, with approximately 70% of cancer-related deaths occurring in middle- and low-income nations. Given these statistics, the use of biomarkers assumes a pivotal role in cancer management. These biomarkers facilitate cancer detection, prognosis estimation, monitoring of treatment responses, and the assessment of resistance development to therapies. This becomes especially critical in disease management. Additionally, the demand for personalized medicines is on the rise, leading to greater collaborations between pharmaceutical and diagnostic entities. For instance, the scientific collaboration formed between DarwinHealth and Prelude Therapeutics in October 2021. This collaboration aims to develop novel biomarkers for multiple oncology candidates, signifying the industry's commitment to advancing diagnostic capabilities.

Drivers for Biomarkers Market:

Rising incidence of cardiovascular diseases such as heart failure, coronary artery disease, and stroke is poised to drive market growth significantly. As these diseases continue to lead the cause of disease prevalence and mortality worldwide, the need for accurate and early diagnostic devices becomes essential. Biomarkers that include genes, proteins, metabolites, and other molecules, offer a possible pathway for identifying the risk of cardiovascular diseases, allowing for timely intervention, personalized treatment strategies, and improving patient outcomes. The need for precise risk assessment, disease monitoring, and customized therapeutic approaches aligns with the growing trend towards personalized medicine and advances in omics technologies, further boosting the development and adoption of biomarkers in the cardiovascular disease landscape. In addition, the use of biomarkers in research and clinical practices, especially in chronic disease management and nutrition, is expected to drive the demand for biomarkers market during the forecast period.

Restrain for Biomarkers Market:

The limited availability of drugs and treatments significantly restrain the growth of the biomarkers market. As biomarkers hold immense promise for personalized medicines and optimize patient treatment outcomes, their potential impact might be hindered by the limited availability of related drugs. In cases where biomarkers identify specific patient populations that could benefit from targeted therapies, the lack of approved drugs tailored to these biomarker-driven indications may impede their effective clinical implementation. These limitations may also impact the biomarker discovery process, drug development, and regulatory approvals.

Opportunities for Biomarkers Market:

The emergence of high-throughput omics technologies has significantly bolstered the discovery-oriented methodology. These advancements have remarkably facilitated the accessibility to quantitative datasets encompassing variably expressed mRNAs, microRNAs, and proteins derived from case-control studies. The transformative landscape accelerated the identification of potential biomarkers and facilitated a comprehensive understanding of molecular signatures associated with the diseases. Integrating these technologies into biomarker research presents a promising opportunity to revolutionize diagnostics, prognostics, and therapeutic strategies. The wealth of data generated boosts the potential for novel biomarkers identification, translation, and validation into clinical practices. Therefore, further propelling the market's growth.

Trend for Biomarkers Market:

A rapidly developing trend in the biomarkers market is the emergence of digital biomarkers. This paradigm shift is mainly attributed to the advancements of sensors and personalized devices, which enable the seamless and continuous assimilation of information about an individual. This data provides insights into complex measures such as psychological well-being, physical activity, dietary patterns, cognitive abilities, mobility, and tremors. Significantly, the need for data collection is primarily driven by novel technologies embedded in smartphones and wearable real-time electronic devices that allow for real-time streaming and shortage of complex data. Moreover, the establishment of robust standards for validating and utilizing these innovative biomarkers is an ongoing trend that holds immense potential to transform the future of healthcare, further driving the biomarkers market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • FutureWise research report will help you understand the growth prospects, key trends, and data points affecting the market's growth.
  • A detailed review of strategies being opted by the players in this market, and a thorough market share registered by the key companies globally as well as on a regional basis.

  • To provide with an exhaustive analysis on the of Biomarkers Market by product & services, by type, by application, by disease indication and by region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Biomarkers Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Biomarkers Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Biomarkers Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Biomarkers Market, Product & Services Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Consumables
        2. Services
        3. Software

  • 8.   Biomarkers Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Safety Biomarkers
        2. Efficacy Biomarkers
        3. Predictive Biomarkers
        4. Surrogate Biomarkers
        5. PharmacodynamicS Biomarkers
        6. Prognostic Biomarkers
        7. Validation Biomarkers

  • 9.   Biomarkers Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diagnostics
        2. Drug Discovery & Development
        3. Personalized Medicine
        4. Disease Risk Assessment
        5. Other Applications

  • 10.   Biomarkers Market, By Disease Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cancer
        2. Infectious Diseases
        3. Immune Disorders
        4. Neurological Disorders
        5. Cardiovascular Disorders
        6. Other Disease Indications

  • 11.   North America Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Biomarkers Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F.Hoffmann-La Roche Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Thermo Fisher Scientific Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abbott Laboratories
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. QIAGEN N.V.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. PerkinElmer, Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck KGaA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bio-Rad Laboratories
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Enzo Biochem, Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Charles River Laboratories International Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Eurofins Scientific
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Related Market

Cancer Biomarkers Market

Read More

EPO Biomarkers Market

Read More

Genomic Biomarkers Market

Read More
Partner

Our Clients